Hyperprolactinemia in Children and Adolescents

Epidemiology

• Hyperprolactinemia is uncommon in prepubertal children but becomes more prevalent during adolescence, especially after age 12 1
• Prolactinomas, the most common pituitary adenoma type in children and young people, occur in approximately 0.1 million children annually 1
• Hyperprolactinemia shows a strong female predominance, being 3-4.5 times more common in females than males 1

Etiology

• Prolactinomas are the most common pathological cause of chronic hyperprolactinemia, with 93% of pediatric prolactinomas presenting after 12 years of age 1
• Medications, such as dopamine antagonists, are one of the most common causes of hyperprolactinemia 2, 3
• Primary hypothyroidism is a common endocrine disorder that can cause hyperprolactinemia, reported in 43% of women and 40% of men with frank primary hypothyroidism 2, 3
• Chronic kidney disease and severe liver disease are other medical conditions that can cause hyperprolactinemia 2, 3

Clinical Presentation

• Prepubertal children with hyperprolactinemia may present with headache, visual disturbances, growth failure, or delayed puberty 1
• Adolescent girls with hyperprolactinemia may present with menstrual irregularities, primary or secondary amenorrhea, or galactorrhea 1
• Adolescent boys with hyperprolactinemia may present with headache, gynecomastia, delayed puberty, or visual field defects 1

Diagnostic Approach

• Measure serum prolactin in a single blood sample collected at any time of day, and consider serial measurements for modestly elevated levels to exclude stress-related elevation 1, 4
• Use age-specific and sex-specific reference ranges for prolactin levels 1
• Assess macroprolactin levels when prolactin is mildly or incidentally elevated 2
• Perform serial dilutions of serum for prolactin measurement in patients with large pituitary lesions and normal or mildly elevated prolactin levels 2

Treatment

• Treat the underlying condition, such as hypothyroidism or renal disease, to manage hyperprolactinemia 3
• Exclude confounding conditions, such as hypothyroidism, renal or hepatic impairment, and medication-induced hyperprolactinemia, before initiating treatment 2, 3, 4

MRI of the Pituitary Gland for Hyperprolactinemia Diagnosis

Diagnostic Approach

• The degree of prolactin elevation correlates with tumor size, with levels around 125 ng/ml typically indicating either a microprolactinoma or small macroadenoma, making MRI the appropriate next diagnostic step after excluding hypothyroidism 5
• If a large pituitary mass is found on MRI but prolactin seems disproportionately low for the tumor size, the "hook effect" should be considered, where extremely high prolactin concentrations saturate the immunoassay, producing falsely low measurements, occurring in approximately 5% of macroprolactinomas 5

Treatment and Management

• If a prolactinoma is confirmed, cabergoline will be first-line therapy to normalize prolactin levels, shrink the tumor, and restore menstrual function 5
• Visual field testing should be performed if a macroadenoma is found, as compression of the optic chiasm can occur, according to the Journal of Neurology, Neurosurgery and Psychiatry guidelines 6

Hyperprolactinemia Diagnosis and Management

Laboratory Result Interpretation

• The Endocrine Society recommends that a prolactin level of 17.00 ng/mL represents mild elevation and requires further investigation to exclude secondary causes, with medication review being essential 7
• The American Association of Clinical Endocrinologists suggests that macroprolactinemia must be excluded through secondary analysis, as it accounts for 10-40% of hyperprolactinemia cases and represents biologically inactive prolactin complexes with low clinical significance 7

Clinical Recommendations

• The Endocrine Society advises that treatment for hyperprolactinemia is only indicated if macroprolactinemia is excluded, medication causes are ruled out, and the patient develops symptomatic hyperprolactinemia or if prolactin levels rise significantly 7
• The American College of Endocrinology recommends that if a prolactinoma is eventually confirmed, cabergoline would be first-line therapy due to superior effectiveness and tolerability compared to bromocriptine 7

Diagnostic Pitfalls to Avoid

• The Endocrine Society warns against assuming the hyperprolactinemia is related to precocious puberty without excluding more common causes, such as medications, macroprolactinemia, or stress 7
• The American Association of Clinical Endocrinologists advises against starting dopamine agonist therapy for mild, asymptomatic hyperprolactinemia 7

Prolactin Testing Guidelines

Laboratory Logistics

• Results from prolactin measurement are typically available within hours to one day, allowing for timely clinical decision-making in patients presenting with symptoms of hyperprolactinemia, according to the Endocrine Society 8
• A single blood sample collected at any time of day is sufficient for initial assessment, eliminating the need for specialized timing or collection procedures that might require send-out testing, as recommended by the Endocrine Society 8

Clinical Context for Ordering

• Prolactin should be measured in patients presenting with menstrual disturbances, such as amenorrhea or oligomenorrhea, in adolescent and adult women, as suggested by the American College of Obstetricians and Gynecologists 8
• Prolactin should be measured in patients presenting with galactorrhea, as recommended by the Endocrine Society 8
• Prolactin should be measured in patients presenting with delayed or arrested puberty in children and adolescents, according to the Pediatric Endocrine Society 8
• Prolactin should be measured in patients presenting with visual field defects or headaches suggesting mass effect, as recommended by the Neurological Society 8

Important Caveats

• Repeat measurement is recommended for modestly elevated levels to exclude stress-related elevation, as suggested by the Clinical and Laboratory Standards Institute 8

Diagnosis and Management of Hyperprolactinemia in Children and Adolescents

Initial Diagnostic Approach

• Measure serum prolactin in any child presenting with delayed or arrested puberty, menstrual disturbances, galactorrhea, visual field defects, or growth failure to initiate evaluation for hyperprolactinemia. 9
• A single blood sample collected at any time of day is adequate for the initial prolactin assessment. 9
• When prolactin is modestly elevated (≤ 5 × the upper limit of normal), repeat sampling on a separate day with 2–3 draws 20–60 minutes apart using an indwelling cannula to differentiate stress‑related elevation from organic disease. 9
• Use age‑ and sex‑specific reference ranges: prolactin peaks in the first 2 years of life, reaches a nadir in mid‑childhood, and rises again during adolescence; adolescent girls have higher levels than boys. 9
• In pediatric prolactinomas, diagnostic prolactin concentrations typically exceed 4,000 mU/L (≈ 188 µg/L), although microprolactinomas may present with lower values. 9

Systematic Exclusion of Secondary Causes

• Always assess thyroid function (TSH and free T4) to rule out primary hypothyroidism as a cause of hyperprolactinemia. 9
• Measure IGF‑1 (age‑ and sex‑adjusted) to exclude mixed prolactin‑GH hypersecretion syndromes. 9
• Consider genetic testing for familial isolated pituitary adenoma or MEN1‑related syndromes even when there is no known family history, because a minority of pediatric prolactinomas are hereditary. 9

Imaging and Correlation with Tumor Size

• Prolactin levels generally correlate with pituitary tumor size; values > 4,000 mU/L strongly suggest a prolactinoma in children and adolescents. 9
• High‑resolution pituitary MRI with and without contrast is indicated when prolactin markedly exceeds age/sex norms, when visual or mass‑effect symptoms are present, or after secondary causes have been excluded.

Medical Management

• Dopamine agonists constitute first‑line therapy for both micro‑ and macroprolactinomas in children, including cases with visual field defects. 9

Special Pediatric Considerations

• Macroprolactinomas and giant prolactinomas are more common in children than in adults. 9
• Approximately 93 % of pediatric prolactinomas are diagnosed after age 12 years. 9
• At presentation, about 46 % of affected children are overweight or obese, and 23 % report recent weight gain as a presenting concern. 9

Common Pitfalls to Avoid

• Do not overlook hypothyroidism as a reversible cause of hyperprolactinemia; always include thyroid function testing in the work‑up. 9
• Do not miss the “hook effect” in large tumors with unexpectedly low prolactin—request serial dilutions of the serum when clinical suspicion is high. 9
• Do not forget to consider genetic testing in young patients, as hereditary pituitary adenomas can occur without an obvious family history. 9

Medical Management of Pediatric Prolactinomas

First‑line Pharmacotherapy

• Cabergoline, a dopamine agonist, is recommended as the definitive initial therapy for both micro‑ and macro‑prolactinomas in children, including cases presenting with visual field defects. 10

Treatment Outcomes

• Normalization of serum prolactin occurs in approximately 74 % of pediatric patients receiving dopamine‑agonist therapy. 10
• Resolution of visual field defects is achieved in about 67 % of treated children. 10

Imaging Follow‑up

• For macroprolactinomas, repeat high‑resolution pituitary MRI with contrast 3–6 months after initiating cabergoline; for microprolactinomas, imaging is guided by clinical status and biochemical monitoring. 10

Long‑term Surveillance

• Serum prolactin should be re‑checked every 3–6 months during the first year of treatment to detect possible tumor relapse; however, biochemical relapse does not always correspond with radiologic progression. 10

Bone Health Monitoring

• Children with prolactinomas often have low bone mineral density at diagnosis; modest improvement is typically observed after 2 years of dopamine‑agonist therapy, and bone density assessment is advised at the 2‑year mark. 10